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In the pol gene of bovine immunodeficiency virus (BIV) there is a sequence, located between the reverse-transcriptase and integrase (IN)-encoding
sequences, that is not found inHIV-1pol gene and encodes a 74-residue polypeptidewith homology to dUTPases.We have expressed twoBIV IN versions
that differ in their amino termini. The longer version, containing the 74-residue sequence, did not show any detectable 3′-end processing and strand transfer
IN activities and performed only the IN-associated disintegration. Consequently, the shorter version, lacking the dUTPase-related residues, performed all
three activities and ismost likely similar to the viral enzyme. A comparison between BIV IN and the well-studied HIV-1 IN, with substrates that mimic the
U5 LTR sequences of BIV, HIV-1 and another bovine lentivirus, Jembrana disease virus, revealed that the extra 3′-end sequence beyond the conserved
“CA” is probably less important for IN activities than the sequence upstream to the “CA".
© 2007 Elsevier Inc. All rights reserved.Keywords: Integrase; Reverse transcriptase; The lentiviruses BIV, Jembrana disease virus and HIV-1; LTR; dUTPase-like segment; 3′-end processing; Strand
transfer; DisintegrationIntroduction
The pathogenesis of lentiviruses is characterized by persis-
tent, life-long infections and a slow progressive disease course in
the naturally infected host. There are wide variations in clinical
symptoms caused by the different members of the lentivirus
subfamily (Gonda et al., 1987; Narayan and Clements, 1989).
Bovine immunodeficiency virus (BIV) is a member of the
lentivirus subfamily of retroviruses that are exogenous and
nononcogenic viruses. BIV was first isolated from a dairy cow
with progressive weakness, persistent lymphocytosis, lymphoid
hyperplasia and central nervous system lesions (Van der Maaten
et al., 1972). Serological studies have shown that BIV is present
worldwide (Cockerell et al., 1992; Forman et al., 1992), and
seropositivity for BIV has been correlated with a decreased milk⁎ Corresponding author. Fax: +972 36407432.
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doi:10.1016/j.virol.2007.09.014production in dairy cattle (McNab et al., 1994). Despite the fact
that an increased incidence of secondary bacterial infections and
encephalitis was reported in herds with high titers of anti-BIV
antibodies (Snider et al., 1996), there is still no conclusive
confirmation that BIV causes directly these syndromes. This is
further complicated by a co-infection with another bovine
retrovirus, bovine leukemia virus, (BLV) that belongs to the
deltaretroviruses (Flaming et al., 1993, 1997). Interestingly, BIV
was induced in experimentally infected rabbits clinical syn-
dromes, including fatal immune dysfunctions that are similar to
acquired immunodeficiency syndrome (AIDS), caused in humans
by human immunodeficiency viruses type 1 and 2 (HIV-1 and
HIV-2, respectively) and inmonkeys or in cats by simian or feline
immunodeficiency viruses, respectively (SIV and FIV) (Kal-
vatchev et al., 1995, 1998).
BIV resembles other lentiviruses in certain aspects of its
pathogenesis, ultrastructure, genome organization and infec-
tious cycle in susceptible cells (Braun et al., 1988; Garvey et al.,
1990; Gonda et al., 1987). Therefore, this lentivirus was
designated BIV to reflect its biological similarity and genetic
relationship to HIV (Gonda et al., 1987); still, BIV cannot infect
human cells in culture (Gonda, 1994). Interestingly, the genome
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addition to the structural genes gag, pol and env, found in all
retroviruses, BIV encodes six putative nonstructural/accessory
genes; vif, tat, rev, vpw, vpy and tmx (Garvey et al., 1990;
Gonda, 1994; Gonda et al., 1987; Oberste and Gonda, 1992;
Oberste et al., 1991, 1993). Genetic variability is one of the
outstanding features of lentiviruses, contributing to their
pathogenesis by enabling them to persist in the host by evading
host cellular defense mechanisms, the immune system as well as
anti-retroviral treatments. As shown for other lentiviruses, BIV
isolates exhibit a remarkable genomic diversity, mainly in the
viral envelope gene (Meas et al., 2001). Nevertheless, the
assessment of the extent of mutations in the reverse tran-
scriptase (RT) region of BIV pol gene has indicated that this
gene is relatively conserved. The RT-encoding region of BIV
genome, like that of HIV, is subjected to purifying selection and
these two lentiviruses probably diverged from a common
progenitor (Cooper et al., 1999). There is no information on the
extent of conservation of the integrase (IN)-encoding region of
the pol gene among BIV isolates.
The retrovirus-encoded IN enzyme plays a key role in the
early steps of the replication process of retroviruses in the
infected cells by processing the DNA product synthesized by
the RT. IN identifies the ends of the linear viral cDNA, trims
them and then accompanies the DNA into the nucleus toFig. 1. A sequence alignment of the amino acids encoded by the IN regions of the pol ge
BH-10, strains. The upper lines represent the amino acids sequence of BIV, as aligned w
residues long and recombinant BIVDU-IN is 353 residues long. The amino terminus of B
DU-IN (PCSP-) includes the 74-residue sequence in the BIV pol gene that is not found in
identical amino acids and double dots indicate homologous residues. The numbers of the
DU-IN or HIV-1 IN). The carboxyl termini are shown up to the pol genes stop codonscatalyze integration into cellular DNA (Asante-Appiah and
Skalka, 1999; Chiu and Davies, 2004; Coffin et al., 1997;
Craigie, 2002; Vandegraaff and Engelman, 2007). Consequent-
ly, two IN activities are cardinal for the integration process. At
first, the IN removes two nucleotides from the 3′-ends of the
viral cDNA long terminal repeats (LTR). This 3′-end processing
reaction is required to position the indispensable “CA”
dinucleotides at the very 3′-ends of the viral DNA. These 3′-
end dinucleotides are conserved among all retroviruses and are
obligatory for the second step of viral DNA integration, namely
the strand transfer. In this step, the 3′ hydroxyls of the terminal
“A” act as nucleophiles that cleave the 5′–3′ phosphodiester
bonds in the target DNA, generating covalent bonds between
the 3′-ends of the donor viral DNA and the 5′-ends of the
cleaved target DNA. Under in vitro conditions, INs catalyze
also the reverse of DNA strand transfer, performing a
disintegration activity that releases the viral DNA and restores
the continuity of the target DNA (Asante-Appiah and Skalka,
1999; Chiu and Davies, 2004; Coffin et al., 1997; Craigie, 2002;
Vandegraaff and Engelman, 2007).
In order to characterize the BIV pol gene products, we have
recently expressed two recombinant versions of BIV RT that
differ in their carboxyl termini, as a result of the low sequence
homology between the putative carboxyl terminus of BIV RT
and other RTs (Avidan et al., 2006). Thus, we have found that thenes of BIVand HIV-1. The sequences are those of the BIV, BIV127 and the HIV-1,
ith the homologous HIV-1 sequence. Recombinant BIV IN was designed to be 279
IV IN (FLEN-) aligns with that of HIV-1 IN (FLDG-). The amino terminus of BIV
HIV-1 and is the dUTPase-related segment (see text). Stars in the lower lines mark
residues are shown next to each line (starting from the amino termini of either BIV
.
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between the RT and IN-encoding sequences), when added to the
carboxyl terminus of the recombinant BIV RT, does not
contribute to the in vitro-assayed RT and even partially disrupts
the RT activities. Therefore, we have suggested that this 74-
residue segment may be required instead to the BIV IN activity,
as part of the amino terminus of this protein (see sequences in
Fig. 1) (Avidan et al., 2006). Interestingly, other non-primate
lentiviruses, such as FIV and equine infectious anemia virus
(EIAV), express a fourth retroviral enzyme (additional to RT, IN
and protease, typical to all retroviruses), namely a dUTPase
(Bergman et al., 1995; Olmsted et al., 1989). This protein is
encoded by a gene located between the RT and IN-encoding
segments, where the BIV-related 74 residues-encoding segment
is located. Moreover, there is some homology between theFig. 2. The disintegration assay of BIV IN,BIVDU-IN andHIV-1 IN. (A)A schematic illu
of oligonucleotides,whichmimic theU5 end of BIV cDNALTR, integrated into target DN
and methods. The 5′-end of the short complementary 20-nt-long oligonucleotide, which i
The disintegration reaction results in cleaving the phosphodiesteric bond 3′ to the “CA” se
of the target DNA. This leads to an increase in the length of the labeled oligonucleotide fro
disintegration performed byBIV IN andHIV-1 IN. In both (B) and (C), all reactionswere c
IN (see Materials and methods). The control lanes show reactions conducted with no INsequence of the 74-residue BIV segment and these lentiviral
dUTPases, exhibiting ClustalW homology scores of 22% and 24%
with the sequences of the dUTPases of FIV and EIAV,
respectively. However, both FIV and EIAV dUTPases are
about 130 amino acids long, namely almost twice the length of
the BIV pol gene-related segment. Thus, the likelihood that the
BIV-derived 74-residue polypeptide may possess such an
independent enzymatic activity is quite low. Moreover, other
retroviruses, of the betaretroviruses group, express another kind
of dUTPases as transframe proteins from the overlap between the
Gag and PR-encoding genes (Coffin et al., 1997; Hizi et al.,
1987; Koppe et al., 1994; Oda et al., 1988; York et al., 1992).
These dUTPases are significantly larger than the lentiviral
enzymes with 250–320 residues (depending on the viral strain).
Even the dUTPases of E. coli and Candida albicans are aboutstration of the disintegration reaction. The substrate for disintegrationwas composed
A (as part of the 75-nt-long substrate, and near the “CA” cleavage site), seeMaterials
s a part of this substrate target DNA, was end labeled with 32P (indicated with a star).
quence, and the subsequent ligation of the labeled oligonucleotide into the remainder
m 20 nt to 63 nt. (B) The disintegration activity of BIV IN and BIVDU-IN. (C) The
onductedwith equal amounts of the substrate andwithBIV IN,BIVDU-INorHIV-1
present.
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Therefore, as far as we know there is no evidence for an active
74-residue-long dUTPase. Still, all dUTPases show a limited
homology (with five conserved motifs) with the BIV protein
segment. It is likely, however, that the 74-residue-long BIV-
derived segment has a biological role since it is also found in
another related bovine lentivirus, the Jembrana disease virus
(JDV) (Chadwick et al., 1995).
To further characterize the BIV pol gene products and to
test our previous suggestion that the dUTPase-related segment
might be part of BIV IN (Avidan et al., 2006), we have
expressed and studied in the research presented herein two
recombinant BIV IN versions that differ in length at their amino
termini, one of them possessing at its amino terminus the
dUTPase-related sequence. These bacterially expressed IN
versions were derived from a plasmid containing the complete
and infectious proviral BIV genome sequence (the BIV127 strain)
(Braun et al., 1988). A comparative study of the catalytic and
molecular properties of these two IN versions was conducted to
assess the importance of this 74-residue terminus to IN activities.
The longer BIV IN version with this extra sequence is
substantially less enzymatically active than the shorter version,
suggesting that the addition of 74-residue at the amino terminus
interferes with the folding of the enzyme. Hence, this result does
not support our previous suggestion that the 74-residue
polypeptide might be part of BIV IN. The shorter (74 residues-
lacking) BIV IN isoform shows substantial catalytic activities,
resembling in most cases those of the well studied IN of HIV-1. A
comparison between BIV IN and HIV-1 IN, with a variety of
substrates that correspond to the U5 LTR ends of BIV, HIV-1 and
another bovine lentivirus, Jembrana disease virus (JDV), revealed
that the sequence located downstream to the conserved “CA” is
not critical for the processing event, whereas the upstream
sequence is presumably more important for performing strand
transfer and thus integration.
In all, investigating the catalytic properties and the sequence
specificity of BIV IN can potentially allow a better understand-
ing of the closely related HIV-1 IN. Moreover, this knowledge
may help in developing new drugs against IN and, thus, against
lentiviral diseases, including acquired immunodeficiency syn-
drome (AIDS).
Results
Construction of plasmids for expressing the BIV IN versions
and protein purification
A comparison between the pol genes of both HIV-1 and BIV
(Fig. 1) has shown that the best fit between HIV-1 IN (288
amino acids in length) and BIV IN is obtained when the BIV IN
protein starts at its amino terminus with the sequence NH2-
FLENIP and ends at the carboxyl terminus with the sequence
IQDGSS-COOH, next to the BIV pol gene stop codon (TGA).
This results in a BIV IN protein that is 279 amino acids long
with a Clustal W score of 35% while aligned with HIV-1 IN. In
most retroviruses, the IN protein is encoded by the genomic
sequence that is adjacent immediately downstream to the RT-coding sequence (Coffin et al., 1997). Therefore, it was
interesting that the sequence homology between BIV IN and
HIV-1 IN starts 74-residue downstream to the putative carboxyl
terminus of BIV RT (with no homolog between this 74-residue
segment and HIV-1 pol gene products, see Fig. 1). As we could
not predict whether this segment is part of the BIV RT, we have
previously expressed two versions of recombinant BIV RT and
concluded that the 74-residue polypeptide might, if anything,
obstruct efficient catalysis (Avidan et al., 2006). Consequently,
we have predicted that the 74-residue segment may be part of
the next protein encoded by the BIV pol gene, namely the
integrase. In the present study, two recombinant BIV IN
versions that differ in their amino termini and share the same
carboxyl terminus were expressed and studied. The first
recombinant BIV IN version was the 279 residues long with
the best fit to HIV-1 IN. The second (designated BIV DU-IN) is
fused at its amino terminus to the 74-residue dUTPase-related
segment and is, therefore, 353 residues long, starting with NH2-
PCSPPE (see Fig. 1).
The genomes encoding the genes for the expression of the
BIV IN isoforms were synthesized by PCR employing as a
template the pBIV127 plasmid containing an infectious
molecular clone of BIV (Braun et al., 1988), as described in
Materials and methods. Both IN versions were designed to
possess six-histidine tags at their amino termini to allow rapid
purification. The plasmid designations are pT5m-6His-BIV IN
and pT5m-6His-BIV DU-IN for expressing the shorter and the
longer BIV IN versions, respectively. The bacterial clones
harboring these plasmids were analyzed for protein expression
by Western blot analyses with anti-his tag antibodies. Indeed it
was apparent that 30 kDa and a 39 kDa his-tagged proteins were
synthesized by the bacteria harboring the BIV IN and BIV DU-
IN expressing plasmids, respectively (data not shown). The BIV
INs were purified by Ni-NTA agarose affinity chromatography,
designed to selectively bind the six-histidine tag-containing
proteins, as described earlier for other recombinant proteins
(Avidan et al., 2003; Perach and Hizi, 1999; Sevilya et al., 2001;
Taube et al., 1998). The purified recombinant BIV IN versions
were assayed for the IN enzymatic activities.
Disintegration activity of BIV IN versions
Under in vitro conditions, integrases can catalyze the
reverse of DNA strand transfer, performing disintegration
activity that releases the viral DNA and restores the continuity
of the target DNA (Chow et al., 1992; Gerton and Brown,
1997). The structural requirements and the substrate sequence
for this reaction are less stringent than those for the forward
reaction (Bushman et al., 1993; Ishikawa et al., 1999);
therefore, we have used disintegration to determine the activity
of the novel recombinant BIV INs and study the preferable
reaction conditions. The disintegration activity of the two BIV
IN versions was assayed using oligonucleotides that mimic a
single ended insertion of the U5 end of the BIV LTR, as
described before for other integrases (Chow et al., 1992; Hizi
and Levin, 2005; Oz et al., 2002; Vincent et al., 1993). The
schematic illustration of the disintegration assay is shown in
Fig. 3. The effect of divalent cations and pH on the disintegration activities of BIV
IN and BIV DU-IN. All assays were performed with the disintegration substrate
(see Fig. 2A). The relative amounts of the labeled 63 nt product and the 20 nt
substrate were determined from the autoradiographs and the amount of 63 nt
product generated as a percentage of the input 20 nt substrate was calculated for
each reaction. (A) The effect of divalent cations on the disintegration activity of
BIV IN. The disintegration activity of 2 pmol of BIV IN was assayed in the
presence of increasing concentrations of either MnCl2 or MgCl2 as the tested
divalent cation. The reactions were conducted at pH 7.8 with HEPES buffer. All
other assay conditions are as described inMaterials andmethods. (B) The effect of
divalent cations on the disintegration activity of BIV DU-IN. The disintegration
activity of 2 pmol of BIVDU-IN was measured as described in (A). (C) The effect
of pH and buffer on the disintegration activity of BIV IN and BIV DU-IN. The
reactions were performed with 2 pmol of either BIV IN or BIV DU-IN with
HEPES buffer at various pH values or with MOPS at pH 7.2. Both buffers were at
a final concentration of 25 mM. The reactions were conducted in the presence of
5 mMMnCl2. The disintegration activities of the INs were measured as described
in (A).
Fig. 4. Sequence alignments of the 3′-ends U5 LTR of HIV-1, BIV and JDV.
The lines represent the nucleotides sequences of the 3′-terminal sequences at
U5-ends. The darken box marks the highly conserved terminal “CA”
dinucleotides. Other similar nucleotides for all three terminal sequences are
framed. The shown sequences are those of the substrates used in this work for
assaying the 3′-end processing and strand transfer activities of the studied INs
(see Materials and methods and Figs. 5–7).
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detailed in the Materials and methods section. Both BIV IN
versions have generated substantial amounts of the 63
nucleotides product (Fig. 2B). A quantitative analysis has
showed that, under the experimental conditions employed, BIV
IN disintegrates approximately 90% of the substrate, whereas
BIV DU-IN has a lower activity of only about 20% of the
substrate.
In order to assess the optimal assay conditions, both BIV IN
versions were tested for their divalent cations and pH
preferences (Fig. 3). Both INs show a clear preference for
Mn+2 over Mg+2 and the highest disintegration activity was
obtained between 5 and 10 mM MnCl2 (Figs. 3A and B). With
the two BIV IN versions, dose–response disintegration
experiments show that the levels of generated product are the
highest in the presence of 2–4 pmol enzymes per 10 μl reaction
mixture (data not show). Both IN versions showed an improved
activity in the presence of 5 μM ZnCl2 (data not shown) and
preferred HEPES buffer with the highest activity achieved at
pH 7.8 (Fig. 3C). These preferable conditions were used for all
INs tested herein and for all IN enzymatic activities studied
(see Materials and methods). It should be noted that similar
divalent cation and pH dependence preferences were also
observed when we have assayed both the 3′-end processing and
strand transfer IN activities.
The BIV disintegration substrate employed here was
designed to have a structural similarity to the efficient disin-
tegration substrate, used recently for assaying the IN of
retrotransposon Tf1 (Hizi and Levin, 2005). It was shown that
this substrate was recognized also by HIV-1 IN and that, despite
having Tf1 sequences, it was at least as active with HIV-1 IN as
with Tf1 IN versions (Hizi and Levin, 2005). Consequently, we
have tested HIV-1 IN disintegration activity with the BIV
disintegration substrate. The disintegration performed by HIV-1
IN with this substrate is lower than the activity of BIV IN, but
similar to BIV DU-IN activity (Fig. 2C). As stated in Materials
and methods, the IN amounts that gave the highest activity were
0.8 pmol per μl or 0.2 pmol per μl for HIV-1 IN and the BIV IN
versions, respectively. Therefore, with the BIV-related sub-
strate, employed here for assaying disintegration, BIV IN has a
higher specific activity than HIV-1 IN.
3′-End processing and strand transfer activities of BIV IN versions
The 3′-end processing and strand transfer IN assays re-
present the overall forward IN-associated activities. The single
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CA/TG dinucleotides pairs. In the case of HIV-1, there are extra
“GT” dinucleotides that are located beyond the highly
conserved 3′-terminal “CA” dinucleotides. This “GT” sequence
is removed by IN, leaving both ends of the linear viral DNA
with 5′-AC overhangs on the opposite strands (Coffin et al.,
1997; Hindmarsh and Leis, 1999; Rausch and Le Grice, 2004).
A similar, 5′-CAGT-3′ sequence, is found in the 3′-ends of both
U3 and U5 of BIV LTR (see Fig. 4) (Garvey et al., 1990; Rausch
and Le Grice, 2004). This 3′-end nucleotide removal, by the 3′-
end processing IN activity, is followed by the INs' DNA-joining
process, known also as the strand transfer step. The DNA
substrates used here were synthetic 20- and 22-mer oligonu-
cleotides that mimic the U5 end of the BIV LTR. The shorter,
20-mer oligonucleotide, is the preprocessed substrate with CA-
3′-end that represents the 3′-end processing product. The 5′-end
of each oligonucleotide was radiolabeled with 32P and each
labeled strand was annealed to its complementary unlabeled
oligonucleotide, yielding the four different substrates illustrated
in Fig. 5A (and their sequences given in Materials and
methods). Substrates 1 and 2 were used for assaying the strand
transfer activity since they are preprocessed and substrates 3 andFig. 5. The 3′-end processing and strand transfer activities of BIV IN versions. (A) A sch
LTR, designed for assaying the forward IN reactions (the sequences are detailed inMateri
a star along with the sequence of the 3′-end of this oligonucleotide. The lengths of ea
substrate. (B) The products of the strand transfer reactions of BIV IN andBIVDU-INwi
bands indicate the lengths of the labeled oligonucleotides in the substrates (1–2 and 3–
(C) The 3′-end processing performed by BIV IN and BIVDU-INwith the 22 nt BIV-rela
same gel (shown in B), which shows the reaction products of substrates 3 and 4. The ge
reactions were conducted with the equal amounts of the specified substrates and BIV
mixtures incubated with no enzyme present.4 allow assaying both 3′-end processing and the subsequent
strand transfer.
The results with substrates 1 and 2, shown in Fig. 5B, indicate
that BIV IN possesses a strand transfer activity, as it generates
products that are longer than the original 5′-end labeled
substrates. On the other hand, BIV DU-IN shows no such
activity that could be detected above background levels of the
control substrate by itself. As to the 3′-end processing activity, a
shorter exposure of the bottom part of the gel indicates that, as in
the case of the strand transfer activity, DU-IN shows with both
substrates no significant processing activity above background
levels. Conversely, the shorter BIV IN version shows a
significant, albeit low, 3′-end processing of substrate 4 (Fig.
5C). Subsequently, there is an apparent further catalysis by BIV
IN of the 3′-end processing product to generate strand transfer
products (Fig. 5B). Interestingly, the amount of the 20 nt product
generated by BIV INwith substrate 4 is substantially higher than
that detected with substrate 3. This implies that the “GT”
extension of the substrate is removed more efficiently while
present as a single stranded overhang rather than when it is part
of a double stranded duplex. In all, under the experimental
conditions employed, BIV DU-IN does not show any detectableematic illustration of the substrates (designated 1–4) that mimic the U5 end of BIV
als andmethods). The 32P 5′-end labeledDNAstrand of each substrate ismarked by
ch oligonucleotide in the tested DNA duplexes are indicated to the right of each
th the four BIV-related substrates (1–4) that are shown inA. The 20-nt or 22-nt-long
4, respectively). The longer bands were generated by the strand transfer reactions.
ted substrates (3 and 4), as recorded by a short exposure of the bottom region of the
nerated 20-nt-long oligonucleotide is the 3′-end processing product. All performed
IN or BIV DU-IN (see Materials and methods). The control lanes show reactions
315O. Avidan, A. Hizi / Virology 371 (2008) 309–3213′-end processing and strand transfer activities (Fig. 5) and
performed only disintegration (Fig. 2); therefore, we have
proceeded and further tested only the shorter version of the
recombinant BIV IN.
BIV INactivity with substrates thatmimic theU5 endofHIV-1LTR
In order to determine the substrate sequence specificity of the
new BIV IN enzyme, we have performed a comparable study
between this IN and the well studied HIV-1 IN. The DNA
substrates used here were the same four substrates used for
assaying BIV IN and BIV DU-IN (see Fig. 5A) as well as two
other substrates (designated 5 and 6) that mimic the HIV-1 LTR
U5 end (see Materials and methods, Figs. 4 and 6A). Substrate 5
is a preprocessed one and is equivalent to the BIV-related
substrate 2, whereas substrate 6 is comparable to substrate 3;
both have been used before for studying processing and strand
transfer of HIV-1 IN (Mazumder et al., 1994; Oz Gleenberg et
al., 2005, 2007; Oz et al., 2002; Rausch and Le Grice, 2004).
The assays of BIV IN with the BIV substrates (1–4), shown
in Fig. 6, were performed for comparative purposes and are a
repeat of those shown in Fig. 5. HIV-1 IN utilizes quite
efficiently these BIV-derived substrates and, similar to BIV IN,
it prefers substrate 2 (that is preprocessed with the extraFig. 6. The activity of BIVandHIV-1 INswith substrates that mimic the BIVandHIV-1 L
mimic the U5 end of HIV-1 LTRwhichwere used for assaying the forward IN reactions (s
each substrate is indicated by a star along with the sequence of the 3′-end of these olig
indicated to the right of each substrate. (B) The strand transfer activities of BIV IN and H
substrates (5 and 6). The 20-nt or 22-nt-long bands specify the lengths of the labeled oligon
and 21-nt-long bands indicate the HIV-1 substrates 5 and 6, respectively (see A). The lon
performed by BIV IN and HIV-1 IN with the 22 nt BIV-related substrates (3 and 4) and t
product of substrates 3 and4; the 19-nt-long band is the processing product of substrate 6, a
corresponds to the reactions performedwith substrates 3, 4 and 6.All reactions shown in pa
BIV IN or HIV-1 IN (see Materials and methods). All control lanes show reactions conddinucleotide overhang on the 5′-end of the complementary
strand) over the preprocessed and blunt-ended substrate 1. It is
apparent that, with the two preprocessed BIV substrates (1 and
2), the specific activity of BIV IN is higher than that of HIV-1
IN, taking also into account that the optimal amount of HIV-1
IN used is four-fold higher that BIV IN (8 pmol versus 2 pmol
per reaction, respectively, see Materials and methods). The
results presented in Fig. 6B show that BIV IN can utilize the
HIV-1 substrate 5 (which has the same structure as substrate 2
but differs in sequence, see Materials and methods and Fig. 4)
for its a stand transfer activity, although this activity is sub-
stantially lower activity than that achieved with the equivalent
BIV substrate 2. HIV-1 IN prefers the self U5 sequence as well,
showing a higher amount of products that were generated with
substrate 5 than with substrates 1 and 2 (Fig. 6B). In summary,
as for the strand transfer activity, each IN prefers its own
terminal sequence.
We have already noticed that, under the experimental condi-
tions employed, the novel BIV IN has a low 3′-end processing
activity even with the self related sequence (Fig. 5C). Therefore,
it could be expected that BIV IN might have an even lower 3′-
end processing activity with the blunt-ended HIV-1 derived
substrate 6. Indeed, BIV IN did not show any detectable
processing activity above background levels with substrate 6TR sequences. (A) A schematic illustration of the substrates (designated 5 and 6) that
equences are given inMaterials andmethods). The 32P 5′-end labeled DNA strand of
onucleotides. The lengths of each oligonucleotide in the DNA duplexes tested are
IV-1 IN with the four BIV-related substrates (1–4 see Fig. 5A) and the HIV-1 related
ucleotide in each substrate (1–2 and 3–4, respectively, see Fig. 5A), whereas the 19-
ger bands were generated by the strand transfer activities. (C) The 3′-end processing
he 21 nt HIV-1 related substrate (designated 6). A 20-nt-long band is the processing
s recorded by a short exposure of the bottomgel part of the same gel (shown inB) that
nels B andCwere performedwith equal amounts of the specified substrates andwith
ucted with no enzyme present.
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enzyme utilizes both the HIV-1 and BIV-derived substrates to
about the same extent (substrates 6 and 3, respectively, Fig. 6C).
As in the case of BIV IN, the 3′-end processing of HIV-1 IN
shows some preference for the BIV substrate 4 over 3,
indicating that both tested INs perform a better with an
overhanged 3′-end processing substrate. Nonetheless, HIV-1 IN
exhibited a higher 3′-end processing activity than BIV IN even
with the BIV-related (substrate 4 in Fig. 6C). Therefore, there
are more available products of this reaction that are substrates
for the subsequent strand transfer reaction of HIV-1 IN.
Consequently, the amount of strand transfer products generated
by HIV-1 IN appears to be similar to that of BIV IN (substrate 4,
Fig. 6B), despite the lower strand transfer activity exhibited by
HIV-1 IN with the BIV-derived strand transfer substrates
(substrate 1 and 2, Fig. 6B).
Activity of BIVand HIV-1 INs with substrates that mimic the JDV
LTR sequence
Jembrana disease virus (JDV) is a bovine lentivirus that
shows high similarity to BIV, especially with the pol gene
organization. Like BIV, JDV has a dUTPase-like encoding
sequence located between RT and IN sequences in its pol gene.Fig. 7. The activity of BIVandHIV-1 INswith substrates thatmimic the JDVLTRsequen
end of JDV LTR and were designed to assay the forward IN reactions (sequences are give
indicated by a star, alongwith the sequence of the 3′-end of this oligonucleotide. The length
each substrate. (B) The strand transfer activities of BIV IN and HIV-1 IN with the four JD
labeled strands. The longer bands were generated by the strand transfer activities. (C) Th
substrates (9 and 10) and assayed as described in Figs. 5C and 6C. The 20-nt-long band is
equal amounts of the specified substrates and with BIV IN or HIV-1 IN (see Materials aA Clustal W pairwise sequence alignment, performed between
BIV and JDV pol genes, yields a score of 66%, while the
alignment of BIV with HIV-1 pol gene yields only a score of
32%. The BIV IN sequence gives a Clustal W score of 69%
when aligned with JDV IN. However, the putative U5 and U3-
LTR ends of the two bovine lentiviruses are not identical. Thus,
in the U5 LTR ends, the extra 3′-terminal dinucleotides (located
3′ to the highly conserved “CA” dinucleotides) in the case of
BIV and HIV-1 are “GT”, whereas the comparable sequence of
JDV is “GC” (Fig. 4). To further study the sequence specificity,
we have used also synthetic oligonucleotides substrates that
mimic the U5-end of the JDV LTR. The substrates were
designed similar to the four BIV U5 substrates (see Figs. 4, 5A
and 7A).
A comparison between the 3′-end processing activities of
BIV IN and HIV-1 IN, with the BIV substrates 3 and 4 and the
equivalent JDV substrate, 9 and 10, reveals similar behaviors
(Figs. 6C and 7C). As shown above, with the BIV-related
substrates 3 and 4 (Figs. 5C and 6C), BIV IN processed the 3′-
end of the terminally recessed substrate 10 and did not have any
detectable processing activity on the blunt-ended substrate 9
(Fig. 7C). The amount of the processing product of substrate 10
is comparable to that of substrate 4, suggesting that the 3′-end
processing activity of BIV IN was not affected by the JDV-ce. (A)A schematic illustration of the substrates (designated 7–10) that mimic theU5
n inMaterials and methods). The 32P 5′-end labeled DNA strand of each substrate is
s of the labeled oligonucleotides in theDNAduplexes tested are shown to the right of
V-related substrates (7–10). The 20-nt or 22-nt-long bands indicate the length of the
e 3′-end processing performed by BIV IN and HIV-1 IN with the 22-nt JDV-related
the processing product. All reactions shown in panels B and Cwere conducted with
nd methods). The control lanes show reactions conducted without any enzyme.
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substrate and shows a high activity with the JDV substrates
(Fig. 7C), similar to the activity found for HIV-1 IN with the
BIV substrates (Fig. 6C).
Along these lines, the strand transfer activity of BIV IN
with substrates 7 and 8 (Fig. 7B) is as high as with the BIV-
derived substrates 1 and 2 (Figs. 5B and 6B). With the JDV
substrates, HIV-1 IN shows a strand transfer activity lower
than that of BIV IN (Fig. 7). This result is similar to the stand
transfer activities of these two INs with the BIV substrates,
where the specific strand transfer activity of HIV-1 IN is lower
than that of BIV IN (Fig. 6B). In summary, both BIV IN and
HIV-1 IN can utilize the JDV-derived sequences for their
forward integrase activities: the 3′-end processing and strand
transfer.
Discussion
The pol gene is the most conserved one among lentiviruses
as well as within their species. The amino acid sequence of the
BIV pol gene shows significant homology to the sequence of
the well-studied HIV-1 with Clustal Walignment pairwise score
of 32% (the same score as for the alignment of BIV and HIV-2
pol genes) (Thompson et al., 1994). Despite the high similarity
between these pol genes, we have noticed in BIV a 74-residue
dUTPase-like segment that is located between the RT and IN-
coding sequences (Fig. 1). As far as we are aware of, there is no
information about an enzymatically active dUTPase that is as
small in size as a 74 residues long polypeptide. Nevertheless,
such a segment (with the same length) is present also in another
related bovine lentivirus, JDV (Chadwick et al., 1995), and gives
an alignment score of 33% with the BIV-derived segment. We
assume that, since these dUTPase-related segments are preserved
in BIV and JDV, they probably have some biological roles.
We have recently expressed two recombinant versions of
BIV RT, which differ in length, in order to study the role of the
dUTPase-like segment of the BIV pol gene (Fig. 1). We have
found that the 74 residues longer recombinant BIV RT version
(BIV RT2) does not exhibit improved in vitro RT activities or
better stability. In this previous research we have concluded that
this dUTPase-like segment may be required to the BIV IN
activity as part of the amino terminus of this protein (Avidan et
al., 2006). Therefore, in the present study, we have expressed
two versions of BIV IN, one that aligns with HIV-1 IN, the 279-
residus-long BIV IN, and a longer one that includes the 74-
residue at its amino terminus, the 353-residue-long BIV DU-IN.
In the absence of data from virus-synthesized IN and in order to
determine the optimal length of the BIV IN protein, we have
studied these two recombinant BIV IN versions and conducted a
comparative study of their catalytic and molecular properties.
Under the experimental conditions employed, the only IN activity
of BIV DU-IN that could be detected was the in vitro reverse of
strand transfer—the disintegration activity (Fig. 2B). The
disintegration activity of BIV IN is about four-fold higher than
that of BIV DU-IN, suggesting that the putative BIV IN is the
short version. By assaying the BIV IN versions for 3′-end
processing and strand transfer activities, we have seen that theDU-IN did not show any detectable levels of these known primary
IN functions (Fig. 5). These data suggest that the presence of 74-
residue at the IN's amino terminus obstructs the catalytic activities
of the enzyme by probably interfering with the folding of the
protein. Therefore, this result does not support the suggestion,
raised in our previous study of BIV RT (Avidan et al., 2006), that
the 74-residue polypeptide might be functional as part of BIV IN.
Three protease-resistant domains were identified in retro-
viral INs (Asante-Appiah and Skalka, 1999; Bushman et al.,
1993; Chiu and Davies, 2004; Coffin et al., 1997; Craigie,
2001, 2002; Ishikawa et al., 1999; Vandegraaff and Engelman,
2007). These are the following: the amino terminal domain
with the conserved HHCC motif is the zinc binding domain.
The catalytic core domain (CCD) that encompasses the D,D-
35-E amino acid sequence motif found in IN proteins from
plants, animal and fungi and also in transposases of bacterial
transposons. The carboxyl terminal domain that is a DNA
binding site and is less conserved than the other two domains.
It was shown, for HIV-1 IN, that the disintegration activity
requires only the CCD (Bushman et al., 1993). Hence, we
assume that the extra 74-residue at the amino terminus of BIV
DU-IN allows only for the core domain of this IN to preserve
its structure and, consequently, to exhibit disintegration
activity, whereas the folding of the other two domains might
be distorted, resulting in an inactivation of the enzyme's 3′-
end processing and strand transfer functions. From these
findings, we conclude that the short version (279 residues in
length), which aligned quite well with HIV-1 IN, is with all
probability much closer to the authentic and biologically
relevant BIV IN.
The function of 74-residue dUTPase-like segment of BIV
(and of JDVas well) still remains a riddle and should be further
studied as a separate pure polypeptide and also as a part of the
BIV RT or a part of the BIV IN, in order to detect a dUTPase
activity. So far, in preliminary studies we could not identify
such an activity in either the BIV RT or BIV IN versions that
include this protein segment (data not shown). On the other
hand, the presence of the gene encoding this dUTPase-related
segment in both BIV and JDV suggests that it may have a
biological role. Therefore, further studies should be performed
to elucidate its potential importance. These should include
identifying the segment in virions and in BIV-infected cells
(using specific anti-peptide antibodies) and disturbing this gene
by mutating it in BIV infectious clones to see how viral
infectivity and growth are affected.
It should be noted that BIV IN was recently studied with
respect to the transcriptional co-activator LEDGF/p75, which is
the major cellular interactor of HIV-1 IN and is critical to
efficient viral replication (Cherepanov, 2006). This work
suggests that lentiviral INs, including BIV IN, interact with
LEDGF/p75 and this host factor is probably involved in the
catalysis of lentiviral DNA integration.
The LTR of retroviruses and some retroelements differ in
their sequences; yet, all known LTRs have “CA” dinucleotides
adjacent to the U3 polypurine tracts (PPT) as well as to the U5
primer binding site (PBS) (Ilyinskii and Desrosiers, 1998;
Rausch and Le Grice, 2004). Retroviral INs have two activities
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3′-end processing and stand transfer. The 3′-end processing
reaction is required to position the “CA” dinucleotide at the 3′-
end of the cDNA for the second step, i.e., the strand transfer that
completes viral integration. Since the “CA” dinucleotides are
conserved among all retroviruses, one obvious question is how
long the recognition sequences of the retroviral INs are.
Moreover, as the U3 and U5 of each virus show, in most
cases, different sequences near the conserved “CA”, it is
important to know how tight the recognition of the sequences is
upstream and downstream to these “CA” ends. In order to study
the sequence specificity of the BIV IN recombinant protein, we
have compared the BIV IN activities with those of the well
studied HIV-1 IN. The BIV IN self substrates were four double-
stranded synthetic oligonucleotides that mimic the U5 LTR of
BIV (1, 2, 3 and 4 see Fig. 5A). The two double-stranded
synthetic oligonucleotides that mimic the U5 LTR of HIV-1 (5
and 6 see Fig. 6A) served as the HIV-derived substrates
(Mazumder et al., 1994; Oz Gleenberg et al., 2005; 2007; Oz et
al., 2002; Rausch and Le Grice, 2004). A third set of substrates
(that mimic the U5 LTR of JDV) was also used herein. In the
JDV-related substrates, the dinucleotide sequence located 3′ to
the conserved “CA” is “GC”, which is different from the
comparable “GT” sequence in the BIV and HIV-1 substrates
(see Figs. 4, 5A, 6A and 7A). The 3′-end processing activity of
both BIV and HIV-1 INs shows no preference for their
homologous “GT” 3′-end over the heterologous “GC” JDV-
derived 3′-ended substrates. BIV IN 3′-processed the self
substrate 4 and the JDV equivalent substrate 10 with similar
efficiencies but showed no processing activity with the blunt-
ended substrates 3, 6 and 9. HIV-1 IN showed similar 3′-end
processing with substrates 4 and 10 and lower (but equal)
activities, while processing the blunt-ended substrates 3, 6 and
9. The 3′-end processing function of both INs assayed was
substantially more active with both “GT” or “GC” overhanged
3′-end substrates (substrates 4 and 10) than with the comparable
blunt-ended substrates (substrates 3, 6 and 9). While examining
the strand transfer reactions, both BIV IN and HIV-1 IN showed
preference for the self substrates, implying that the binding of
the IN to the self sequence might be stronger, resulting in
generating the correct enzyme-DNA conformation for
performing the strand transfer function. This conclusion is in
line with the finding that the carboxyl terminal DNA binding
domain of INs is less conserved among various INs (Bushman
et al., 1993; Craigie, 2002; Ishikawa et al., 1999). In all, these
findings suggest that the sequence downstream to the conserved
“CA” is not crucial for the processing event, whereas the
upstream sequence is significantly more important for
performing strand transfer and thus integration.
The search of new antiviral drugs requires knowledge of the
functional proteins that are essential for the viral life cycle.
Since integrases have a key role in the retroviruses life cycle, we
have attempted here to reveal some of their specificities. The
data presented indicate that INs show some specificity for the
3′-end LTR termini sequences of donor DNA molecules.
Further studies of the protein–DNA complex that mediates
integration may help in designing novel IN inhibitors.Moreover, the study of retroviral integration is important for
designing safe retroviral vectors for gene therapy that rely on
viral integration.
Materials and methods
Plasmids construction and protein expression
We have expressed and studied two recombinant forms of
BIV IN, designated BIV IN and BIV DU-IN. The DNA
segments that encode the two IN isoforms were generated by
PCR using the plasmid pBIV127, which contains an infectious
proviral clone of BIV DNA (Braun et al., 1988), generously
provided by the “NIH AIDS Research & Reference Reagent
Program”. Both BIV IN versions were designed to end with the
same carboxyl terminus with the sequence IQDGSS-COOH,
prior to the BIV pol gene stop codon (TGA), whereas the amino
termini of DU-IN is 74 amino acids upstream to that of IN.
These IN versions were expressed in E. coli by plasmids similar
to those used previously for the expression of the RTs of HIV-1,
HIV-2 and BIV (Gao et al., 1998; Sevilya et al., 2001). All
synthetic BIV protein-encoding genes were generated by PCR
with the high fidelity Dynazyme polymerase (purchased from
Finnzames), using the appropriate synthetic oligonucleotides.
The BIV IN-encoding segment (nucleotides 3904–4743
including the stop codon) was subcloned from the BIV proviral
clone (Braun et al., 1988) into the pT5M-Nco-6His plasmid and
designated pT5M-6His-BIV IN. The IN-encoding gene (to
which an NcoI site, including a Val codon upstream to the IN
amino terminus, and a HindIII site were added) was subcloned
by ligating the NcoI–HindIII cleaved PCR product into the
NcoI–HindIII cleaved plasmid. The BIV DU-IN-encoding
segment (nucleotides 3682–4743 including the stop codon)
has internal NcoI and HindIII sites. Therefore, for the con-
struction of the BIV DU-IN expression plasmid, the PCR-
synthesized DNA segment (to which SphI and EcoRI sites were
added) was cleaved with SphI and EcoRI and ligated into the
pT5mM-Sph-6His vector cleaved by SphI–EcoRI. The BIV
DU-IN-expressing plasmid was designated pT5M-6His-BIV
DU-IN.
The subcloned BIV-related DNA segments were sequenced
to verify the authenticity of the expressed proteins. These
constructed plasmids express each the BIV IN and the BIV DU-
IN after the induction by isopropyl β-tiogalactopyranoside in
the E. coli strain BL21(DE3)pLysS, grown in NZY broth. To
allow a fast affinity purification of the recombinant INs, the BIV
IN versions were engineered to contain six-histidine tags at their
amino termini. The proteins were purified by using Ni-NTA
agarose affinity chromatography that selectively binds the six-
histidine tag-containing proteins, as we described earlier for
other recombinant proteins (Avidan et al., 2006; Avidan et al.,
2003; Perach and Hizi, 1999; Sevilya et al., 2001; Taube et al.,
1998).
The HIV-1 IN used for this work was purified from a
bacterial clone of the IN coding region from the BH-10 strain of
HIV-1. The vector expressing the six-histidine tag-HIV-1 IN
was pIN10, introduced into E. coli BL21(DE3)pLysS cells as
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2002).
Substrates for INs enzymatic activities
All oligonucleotides, used for assaying INs disintegration,
processing and strand transfer, were gel purified. The 75-
nucleotide-long disintegration substrate was: 5′-TGTTGGGTGT-
TCTTCTTTGAAGAACACCCAACAGTGCAGCGGGTTTC-
CCGCTGCACGGTAAAGCTTGCCGCATACG-3′ and the
short complementary 20 nucleotides long substrate was: 5′-
CGTATGCGGCAAGCTTTACC-3′ (see scheme in Fig. 2A). A
part of the long oligonucleotide, near the “CA” cleavage site,
corresponds to the BIV U5 LTR.
Ten double-stranded short synthetic DNA fragments were
used as substrates for assaying 3′-end processing and strand
transfer (see schemes in Figs. 5A, 6A, 7A), 1–4 that are related to
BIV U5 LTR, 5 and 6 with the IN recognition sequence of HIV-1
U5 LTR and 7–10 that mimic the relevant sequence of JDV U5
LTR (a comparison of these sequences is given in Fig. 4).
Substrate 1: 20 nt, 5′-GCGGTGAAGAACACCCAACA-3′
annealed to the 20 nt 5′-TGTTGGGTGTTCTTCACCGC-3′.
Substrate 2: 20 nt, 5′-GCGGTGAAGAACACCCAACA-3′
annealed to the 22 nt 5′-ACTGTTGGGTGTTCTTCAC-
CGC-3′.
Substrate 3: 22 nt, 5′-GCGGTGAAGAACACCCAACAGT-
3′ annealed to the 22 nt 5′-ACTGTTGGGTGTTCTTCAC-
CGC-3′.
Substrate 4: 22 nt, 5′-GCGGTGAAGAACACCCAACAGT-3′
annealed to the 20 nt 5′-TGTTGGGTGTTCTTCACCGC-3′.
Substrate 5: 19 nt, 5′-GTGTGGAAAATCTCTAGCA-3′
annealed to 21 nt 5′-ACTGCTAGAGATTTTCCACAC-3′.
Substrate 6: 21 nt, 5′-GTGTGGAAAATCTCTAGCAGT-3′
annealed to the 21 nt 5′-ACTGCTAGAGATTTTCCACAC-3′.
Substrate 7: 20 nt, 5′-CGAACAAGAACCACCCAACA-3′
annealed to the 20 nt 5′-TGTTGGGTGGTTCTTGTTCG-3′.
Substrate 8: 20 nt, 5′-CGAACAAGAACCACCCAACA-3′
annealed to the 22 nt 5′-GCTGTTGGGTGGTTCTTGTTCG-3′.
Substrate 9: 22 nt, 5′-CGAACAAGAACCACCCAACAGC-3′
annealed to the 22 nt 5′-GCTGTTGGGTGGTTCTTGTTCG-3′.
Substrate 10: 22 nt, 5′-CGAACAAGAACCACCCAACAGC-
3′ annealed to the 20 nt 5′-TGTTGGGTGGTTCTTGTTCG-3′.
Fifty picomoles of one strand of each substrate (as illustrated in
Figs. 2A, 5A, 6A, and 7A) was 5′-end labeled using 1 unit of T4
polynucleotide kinase (Boehringer Mannheim) and 50 μCi of
[γ-32P] ATP (NEN), in a final volume of 50 μl T4 polynucleotide
kinase buffer for 30 min at 37 °C. The samples were heat-
inactivated and each labeled DNAwas annealed to an equimolar
amount of the appropriate complementary oligonucleotide in
50 mM Tris–HCl (pH 7.5) and 150 mM NaCl.
Assays for integrases activities
Reaction mixtures for assaying INs disintegration, 3′-
processing and strand transfer (in the final volumes of 10 μl)contained, unless otherwise stated, 1 pmol of the DNA
substrate, reaction buffer [25 mM HEPES (pH 7.8), 5 mM
MnCl2, 5 mM CHAPS, 2 mM dithiothreitol, 5 μM ZnCl2, 5%
glycerol] and 2 pmol of BIV IN or BIV DU-IN or 8 pmol of
HIV-1 IN. Incubations were carried out for 30 min at 37 °C and
the reactions were stopped by adding 10 μl stop solution/
loading buffer [90% formamide, 10 mM EDTA, 10 mg/ml
bromophenol blue and 10 mg/ml xylene cyanol]. The 3 min at
100 °C-denatured reaction products were loaded, after fast
cooling on ice, on 14% polyacrylamide–6 M urea denaturing
gels, followed by a high voltage electrophoresis. Gels were
dried and subjected to autoradiography at −80 °C for
visualization and analysis of the resulting products. We have
found that these assay conditions are optimal for assaying both
BIV IN versions and HIV-1 IN and for all tested enzymatic
reactions. These conditions for assaying HIV-1 IN, despite
being somewhat different than those previously employed by us
for assaying this IN (Oz Gleenberg et al., 2005, 2007; Oz et al.,
2002), gave activity levels as high as those obtained with the
previously published conditions (data not shown). It should be
also noted that dose–response reactions have revealed that the
highest activity levels of the BIV-related IN versions were
obtained with 2 pmol BIV IN or with 8 pmol HIV-1 IN (per
reaction).
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